Halozyme Therapeutics, Inc. (NASDAQ:HALO) Shares Bought by Koa Wealth Management LLC

Koa Wealth Management LLC lifted its position in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 1.2% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 74,483 shares of the biopharmaceutical company’s stock after acquiring an additional 915 shares during the quarter. Halozyme Therapeutics accounts for about 3.3% of Koa Wealth Management LLC’s holdings, making the stock its 8th biggest position. Koa Wealth Management LLC’s holdings in Halozyme Therapeutics were worth $4,263,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also modified their holdings of HALO. GAMMA Investing LLC increased its holdings in Halozyme Therapeutics by 96.6% during the 2nd quarter. GAMMA Investing LLC now owns 517 shares of the biopharmaceutical company’s stock valued at $27,000 after acquiring an additional 254 shares in the last quarter. International Assets Investment Management LLC purchased a new position in shares of Halozyme Therapeutics during the 2nd quarter worth approximately $33,000. Skandinaviska Enskilda Banken AB publ acquired a new position in shares of Halozyme Therapeutics during the 2nd quarter worth approximately $49,000. Toth Financial Advisory Corp purchased a new stake in Halozyme Therapeutics in the 3rd quarter valued at approximately $57,000. Finally, FSC Wealth Advisors LLC acquired a new stake in Halozyme Therapeutics during the 3rd quarter valued at $65,000. Institutional investors and hedge funds own 97.79% of the company’s stock.

Insider Transactions at Halozyme Therapeutics

In other news, CEO Helen Torley sold 10,000 shares of Halozyme Therapeutics stock in a transaction dated Thursday, September 12th. The stock was sold at an average price of $59.20, for a total value of $592,000.00. Following the transaction, the chief executive officer now directly owns 676,744 shares of the company’s stock, valued at $40,063,244.80. The trade was a 1.46 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this link. Insiders sold a total of 70,000 shares of company stock worth $4,042,500 in the last ninety days. Insiders own 2.40% of the company’s stock.

Halozyme Therapeutics Stock Performance

NASDAQ:HALO opened at $45.65 on Friday. The company has a market cap of $5.81 billion, a P/E ratio of 15.12, a P/E/G ratio of 0.54 and a beta of 1.29. The firm’s 50 day moving average is $56.04 and its two-hundred day moving average is $53.27. Halozyme Therapeutics, Inc. has a fifty-two week low of $33.15 and a fifty-two week high of $65.53. The company has a quick ratio of 9.15, a current ratio of 10.36 and a debt-to-equity ratio of 3.32.

Wall Street Analyst Weigh In

HALO has been the subject of a number of analyst reports. Wells Fargo & Company cut Halozyme Therapeutics from an “overweight” rating to an “equal weight” rating and boosted their price target for the stock from $58.00 to $62.00 in a report on Monday, October 7th. JPMorgan Chase & Co. downgraded shares of Halozyme Therapeutics from an “overweight” rating to a “neutral” rating and boosted their target price for the company from $52.00 to $57.00 in a research note on Thursday, September 19th. Piper Sandler raised their price target on shares of Halozyme Therapeutics from $51.00 to $52.00 and gave the stock a “neutral” rating in a research note on Monday, November 4th. Cowen reissued a “buy” rating on shares of Halozyme Therapeutics in a research report on Friday, October 18th. Finally, Benchmark reissued a “buy” rating and set a $60.00 price objective on shares of Halozyme Therapeutics in a research note on Thursday, August 8th. Four analysts have rated the stock with a hold rating and seven have issued a buy rating to the company. Based on data from MarketBeat, Halozyme Therapeutics presently has a consensus rating of “Moderate Buy” and an average price target of $61.11.

Halozyme Therapeutics Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.